Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (5): 722-727    DOI: 10.12892/ejgo4342.2019
Original Research Previous articles | Next articles
Metabonomics study of the serum from ovarian cancer patients
Li Li1, *(), Yan Ma1, Shuang Liu1, Xinyan Xu1
1Department of Gynecology, Affiliated Tumor Hospital of Xinjiang Medical Univesity, Urumqi, China
Download:  PDF(1122KB)  ( 181 ) Full text   ( 7 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Objective: Metabonomics may identify potential metabolite markers for ovarian cancer diagnosis. The authors report a metabonomics study of ovarian cancer serum, aiming to identify a distinct serum metabolome of ovarian cancer with diagnostic potential. Materials and Methods: Serum metabolites from diagnosed ovarian cancer patients and healthy subjects were profiled using gas chromatography coupled with mass spectrometry (GC-MS). Results: Differential metabolites of 36 chemicals were identified with statistical tests of orthogonal partial least-squares-discriminant analysis (VIP > 1.2) and the t-test (p < 0.05), being able to differentiate ovarian cancer patients from the healthy controls. The authors observed an altered metabolome in ovarian cancer patients, including glycolysis and tricarboxylic acid (TCA) cycle, urea cycle, glutamine, fatty acids, and proline metabolism. A panel of three serum metabolite markers, containing beta-alanine, palmitic acid and proline, can differentiate ovarian cancer patients from healthy controls with an area under curve (AUC) of 0.995 in the receiver operating characteristic (ROC) analysis. Conclusion: The present results demonstrated that metabonomics is of great potential for finding a non-invasive diagnostic method for the detection of ovarian cancer.

Key words:  Metabonomics      Serum      Ovarian cancer      Gas chromatography coupled with mass spectrometry (GC-MS)      Principal component analysis (PCA)      Partial least-squares-discriminant analysis (OPLS-DA)     
Published:  10 October 2019     
*Corresponding Author(s):  LI LI     E-mail:  lilidoc@163.com

Cite this article: 

Li Li, Yan Ma, Shuang Liu, Xinyan Xu. Metabonomics study of the serum from ovarian cancer patients. European Journal of Gynaecological Oncology, 2019, 40(5): 722-727.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4342.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I5/722

[1] Buse Güler, Merve Çamlıbel, Samiye Mete. What Do Relatives of Turkish Women with Ovarian Cancer Share on Websites? : A Qualitative Research[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 732-738.
[2] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[3] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[4] Qinglian Ma, Wenjie Yan, Jing Yang, Haiyan Wang, Weixiang Wang, Minghui Dong. Functional interpretation of ovarian cancer in correlation with ISGF3 expression pattern[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 769-773.
[5] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[6] Jae Hong Sang, Soo-Ho Chung. Is it enough in ovarian cancer staging surgery to laparoscopic surgery? Comparison of surgical methods[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 541-544.
[7] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[8] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[9] Xifang Lv, Amanguli, Ping Yang. The role of sodium hydrosulfide in the proliferation and apoptosis of exogenous SB203580 pre-treated human ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 622-628.
[10] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[11] F. Oyama, Y. Asano, H. Shimoda, K. Horie, J. Watanabe, Y. Yokoayama. Morphological analysis of peritoneal dissemination of ovarian cancer based on levels of carbonyl reductase 1 expression[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 352-360.
[12] C.J. Heesterbeek, A.M. Thijs, R.H.M. Hermans, D. Boll, G.-J. Creemers. Bevacizumab in combination with metronomic oral cyclophosphamide: an effective and well-tolerated treatment for patients with recurrent ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 364-367.
[13] S.R Oh, J.-W. Park. Is the Risk of Malignancy Index a predictive tool for preoperative differentiation between borderline ovarian tumor and ovarian cancer?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 368-374.
[14] T. Shoji, E. Takatori, M. Kagabu, M. Futagami, Y. Yokoyama, H. Tokunaga, N. Yaegashi, T. Ohta, T. Watanabe, T Sugiyama. Relationship between usefulness of irinotecan and pegylated liposomal doxorubicin therapy and the UGT1A1 genotype in patients with recurrent ovarian cancer (TGCU 104 study)[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 380-385.
[15] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
No Suggested Reading articles found!